| 6.11 -1.2 (-16.42%) | 01-13 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 9.37  |
1-year : | 10.81 |
| Resists | First : | 8.02 |
Second : | 9.26 |
| Pivot price | 7.52 |
|||
| Supports | First : | 6.01 |
Second : | 5 |
| MAs | MA(5) : | 7.63 |
MA(20) : | 7.66 |
| MA(100) : | 8.57 |
MA(250) : | 9.14 |
|
| MACD | MACD : | -0.4 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 30.5 |
D(3) : | 56.5 |
| RSI | RSI(14): 28.4 |
|||
| 52-week | High : | 18.54 | Low : | 4.29 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ CVRX ] has closed below the lower bollinger band by 14.0%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 25.7% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.62 - 7.66 | 7.66 - 7.7 |
| Low: | 5.93 - 5.98 | 5.98 - 6.02 |
| Close: | 6.05 - 6.12 | 6.12 - 6.17 |
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. It offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure (HF) with reduced ejection fraction or systolic HF. The company sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, rest of Europe, and internationally. CVRx, Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Tue, 13 Jan 2026
$CVRX stock is down 14% today. Here's what we see in our data. - Quiver Quantitative
Tue, 13 Jan 2026
CVRx expects 11-18% revenue growth in 2026 following CPT code transition - Investing.com Nigeria
Mon, 12 Jan 2026
CVRx reports preliminary 2025 results, issues 2026 guidance - MSN
Mon, 12 Jan 2026
CVRx Establishes At-The-Market Equity Offering Program - TipRanks
Mon, 12 Jan 2026
Cvrx Inc - on Jan 9, amends existing loan and security agreement dated Oct 31 2022 - SEC filing - marketscreener.com
Mon, 12 Jan 2026
Cvrx Inc - On Jan 9, Amends Existing Loan And Security Agreement Dated Oct 31 2022 - SEC Filing - TradingView — Track All Markets
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Medical - Devices
|
|
| Shares Out | 26 (M) |
| Shares Float | 18 (M) |
| Held by Insiders | 4.3 (%) |
| Held by Institutions | 64.9 (%) |
| Shares Short | 1,490 (K) |
| Shares Short P.Month | 1,500 (K) |
| EPS | -2 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.84 |
| Profit Margin | -93 % |
| Operating Margin | -83.6 % |
| Return on Assets (ttm) | -26.4 % |
| Return on Equity (ttm) | -91.9 % |
| Qtrly Rev. Growth | 9.8 % |
| Gross Profit (p.s.) | 1.8 |
| Sales Per Share | 2.13 |
| EBITDA (p.s.) | -1.9 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -38 (M) |
| Levered Free Cash Flow | -23 (M) |
| PE Ratio | -3.08 |
| PEG Ratio | 0 |
| Price to Book value | 3.32 |
| Price to Sales | 2.86 |
| Price to Cash Flow | -4.17 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|